• Google

    BioMarin Pharmaceutical’s (BMRN) Hold Rating Reaffirmed at Barclays /Link



    Barclays restated their hold rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a report released on Sunday, August 5th. The brokerage currently has a $98.00 price objective on the biotechnology company’s stock, up from their previous price objective of $95.00. BMRN has been the subject of a number of other research reports. Credit Suisse Group […]




    (@)Philip Parker

    Published on 21 Aug 2018 at 08:55AM

    Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN) CarMax, Inc  Receives $83.41 Average PT from Analysts Biogen Inc  Receives $367.12 Consensus PT from Analysts Enjin Coin  Market Cap Hits $28.18 Million Brokerages Set Hess Corp.  PT at $59.96 Norfolk Southern  Stock Rating Upgraded by Loop Capital Web Analytics share news on Facebook tweet this investment news share on linkedin share on StockTwits share on Google Plus share on reddit



















  • Recent Posts








    ^Comments